Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Pfizer (NYSE:PFE) with a Market Perform ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The company's strong cash flow supports continued dividend growth and business ...

For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of ...

The stock's rise snapped a three-day losing streak.

Real-time index price for S&P 500 Energy [Sector] (SREN), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...

VWAP, or volume-weighted average price, is a technical analysis tool used primarily on intraday charts. It provides a benchmark for ... It allows them to monitor price movements throughout the trading ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

While shares have posted break-even returns so far in 2024, Pfizer stock has cratered by more than 30% over the ...